1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Polynovo Limited

Polynovo Limited

CALZF
Polynovo LimitedUS flagOther OTC
0.71
USD
+0.03
- -
490.64MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
0.01
0.01
0.01
0.02
0.03
0.04
0.06
0.1
0.15
0.18
Basic EPS, GAAP
- -
-0.01
- -
-0.01
-0.01
-0.01
- -
-0.01
-0.01
- -
-0.01
0.01
0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
-0.01
-0.01
-0.01
- -
- -
- -
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.02
0.01
0.04
0.03
0.06
0.05
0.04
0.04
0.03
0.1
0.11
0.13
Tangible Book Value per Share
0.02
0.01
0.01
0.03
0.01
0.04
0.04
0.03
0.03
0.02
0.09
0.1
0.12
Basic Weighted Avg Shares
347
411
419
493
562
628
660
661
661
661
684
690
691
Sales/Revenue/Turnover
- -
- -
- -
3
4
6
13
22
29
41
65
103
127
Operating Margin (%)
- -
-7,430.47
-132,296.1
-133.45
-165.28
-124.05
-34.19
-18.69
-10.79
-0.62
-9.48
1.13
3.52
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
1
2
2
2
3
Net Income, GAAP
-1
-3
-1
-3
-5
-6
-3
-4
-5
-1
-5
5
13
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-5,302.72
-43,414.87
-93.43
-138.36
-104.54
-23.9
-18.93
-15.79
-2.88
-7.55
5.1
10.38
Working Capital
4
5
4
12
7
25
18
10
8
8
55
56
49
LT Debt
- -
- -
- -
- -
- -
- -
- -
4
7
9
14
13
15
Total Equity
8
9
7
15
11
28
26
24
22
18
65
72
83
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-22.18
-43.38
-20.69
-22.31
-25.68
-22.96
-9.46
-13.74
-17.58
-5.08
-10.57
7.22
16.08

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
49%
53.59%
15.44%
Free Cash Flow
352.17%
107.03%
380.88%
Net Income, GAAP
39.58%
38.6%
151.17%
Sales/Revenue/Turnover
10,961.52%
42.53%
23.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
65
2024
- -
- -
- -
- -
103
2025
- -
- -
- -
- -
127

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Bruce Peatey
Full Time Employees
301
Sector
Healthcare
Industry
Biotechnology
Address
320 Lorimer Street Port Melbourne VIC Australia 3207
IPO Date
Oct 2, 2009
Website
polynovo.com
Similar Companies
Malachite Innovations, Inc. (MLCT)
Sorrento Therapeutics, Inc. (SRNEQ)
Inovio Pharmaceuticals, Inc. (GBM.F)
NervGen Pharma Corp. Common stock (NGEN)
Cardiff Oncology, Inc. (CRDF)
ForU Holdings, Inc. (FORU)
Business
PolyNovo Limited (ASX:PNV; OTC:CALZF), an Australia-based medical technology company founded in 1998 and headquartered in Port Melbourne, Victoria, designs, develops, manufactures and sells biodegradable medical devices utilizing its patented NovoSorb bioabsorbable polymer technology for advanced wound care and tissue regeneration; its core products include NovoSorb Biodegradable Temporizing Matrix (BTM), a synthetic dermal scaffold to support dermis regeneration in cases of extensive surgery, trauma or burns, NovoSorb MTX for single-stage grafting in burns, chronic and surgical wounds, hernia repair devices for ventral hernia and complex abdominal wall reconstruction, and NovoSorb Dermal Beta Cell, an intracutaneous ectopic pancreas under development to treat type 1 diabetes; the company also distributes SUPRATHEL, an epidermal skin substitute for mid-dermal burns, donor sites and abrasions. PolyNovo operates primarily in the medical and surgical equipment manufacturing industry, with geographic reach spanning Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong and over 40 additional countries, serving clinicians managing acute complex wounds from burns, trauma and surgery; it generates the majority of revenue from U.S. sales of NovoSorb BTM, employing approximately 300 staff and reporting total revenue of A$129 million in fiscal 2025. In recent developments, PolyNovo acquired exclusive sales and distribution rights for SUPRATHEL in the UK, Australia and New Zealand from PolyMedics in May 2024, marking its first third-party product distribution alongside the NovoSorb portfolio to broaden complex wound care options; the company continues to expand its manufacturing facility and headquarters in Port Melbourne to support product innovation, clinical trials including prior BARDA-funded burns studies, and global growth, with 72% more patients treated in the fiscal 2025 half-year versus the prior period.

Company News

APIChatGPT

  • seekingalpha.com

    PolyNovo Limited (CALZF) Q2 2026 Earnings Call Transcript